Register now for this upcoming Endo-ERN webinar.

Genetic obesity is associated with difficulties in the regulation of appetite and satiety, often resulting in behavioural difficulties around food and consequent severe obesity. GLP-1 agonists affect appetite and satiety and may benefit these patients. In this webinar, the role of GLP-1 agonists in genetic obesity conditions such as Bardet Biedl, Alström and Prader-Willi syndromes will be discussed, and the impact of behaviour on the patient and carers will be explored.

Chaired by MTG5 Chairs Charlotte Höybye, Adult chair, Karolinska University Hospital, Sweden & Susan O’Connell, Paediatric chair, Children’s Health Ireland, Ireland

Speakers:

– Julia von Schnurbein, Ulm University Medical Center, Germany

– Tony Goldstone, Imperial College Healthcare NHS Trust

– Bernd Rosenbichler, Alström Syndrom e.V.

You will have the opportunity to ask questions directly at the end of the webinar.

Unable to attend live? Register and you will receive a recording of the webinar afterwards.

Learning outcomes: After attending the webinar attendees will have a greater understanding of the possible use of role of GLP-1 agonists in genetic obesity conditions such as Bardet Biedl, Alström and Prader-Willi syndromes. In addition the impact of patient behaviour and carers will be explored.

 

An application for accreditation has been submitted to European Accreditation Council for Continuing Medical Education (EACCME).